The hormonal contraceptive market was valued at $17.32 billion in 2023 and is estimated to reach $26.62 billion by 2035, exhibiting a CAGR of 3.6% from 2024 to 2035. Hormonal contraceptives are medications that use synthetic hormones to prevent pregnancy by inhibiting ovulation, thickening cervical mucus to block sperm, and altering the uterine lining to prevent implantation. They are available in various forms, including birth control pills, patches, injections, vaginal rings, and intrauterine systems containing hormones. Combined hormonal contraceptives contain both estrogen and progestin, while progestin-only options, such as the mini-pill and certain IUS, are suitable for individuals who cannot take estrogen.
The growth of the hormonal contraceptive market is driven by rise in prevalence of unintended pregnancies, rise in awareness about family planning, and increase in government initiatives promoting contraceptive use. According to a 2023 article by National Library of Medicine, 208 million pregnancies are expected to occur globally each year, with 46% of them becoming unintended. Factors such as lack of access to contraception, inadequate sex education, and inconsistent use of birth control methods contribute to rise in incidence of unintended pregnancies globally. Hormonal contraceptives, including oral pills, injectables, patches, and implants, offer reliable and convenient options for preventing pregnancy, leading to their widespread adoption of hormonal contraception.
In addition, increase in awareness about family planning is a significant factor driving the growth of the hormonal contraceptive market. As access to information improves globally, more individuals are recognizing the benefits of family planning for personal health and socio-economic stability. Educational campaigns and healthcare initiatives, especially in developing regions, have helped inform people about reproductive health and contraceptive options. This awareness is empowering individuals, particularly women, to make informed decisions about their reproductive health, leading to high demand for hormonal contraceptives. Furthermore, governments and non-governmental organizations are playing a crucial role in promoting family planning services, offering counseling, and distributing contraceptive methods. In 2017, the Government of India launched Mission Parivar Vikas to significantly improve access to contraceptives and family planning services in high-fertility districts of seven states with a total fertility rate of 3 or higher. In December 2024, the government expanded the initiative to include six North-Eastern states, alongside the original seven high-focus states, to further enhance access to contraceptives and family planning services.
Cultural shifts and social acceptance have become significant drivers in the growth of the hormonal contraceptive market. The growing awareness regarding family planning and reproductive health has led to more individuals and couples seeking contraceptive options that align with their personal and lifestyle choices. Awareness campaigns, educational initiatives, and ongoing discussions on sexual and reproductive rights have enabled individuals to make informed decisions about family planning. Also, the increasing acceptance of diverse family structures and the trend toward delayed childbearing have fueled the demand for effective, convenient, and reliable contraceptive options.
The hormonal contraceptive market is segmented on the basis of product, hormones, end user, age group, and region. On the basis of product, the market is divided into oral contraceptive pills, injectable birth control, emergency contraceptive pills, and vaginal rings, transdermal patches, and IUS & Implants. On the basis of hormones, the market is divided into progestin only contraceptive, and combined hormonal contraceptive.
On the basis of age group, the market is categorized into 15 to 24 years, 25 to 34 years, 35 to 44 years, and above 44 years. On the basis of end user, the market is segmented into hospitals, household, and clinics. On the basis of region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (France, Germany, Italy, Spain, UK, Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA).
Major key players that operate in the global hormonal contraceptive market are Teva Pharmaceutical Industries Ltd., Bayer AG, Pfizer Inc, Johnson and Johnson, AbbVie Inc., Lupin Pharmaceuticals, Inc., Organon & Co, Afaxys, Inc., Pregna International Limited, and Mayne Pharma Group Limited.
The growth of the hormonal contraceptive market is driven by rise in prevalence of unintended pregnancies, rise in awareness about family planning, and increase in government initiatives promoting contraceptive use. According to a 2023 article by National Library of Medicine, 208 million pregnancies are expected to occur globally each year, with 46% of them becoming unintended. Factors such as lack of access to contraception, inadequate sex education, and inconsistent use of birth control methods contribute to rise in incidence of unintended pregnancies globally. Hormonal contraceptives, including oral pills, injectables, patches, and implants, offer reliable and convenient options for preventing pregnancy, leading to their widespread adoption of hormonal contraception.
In addition, increase in awareness about family planning is a significant factor driving the growth of the hormonal contraceptive market. As access to information improves globally, more individuals are recognizing the benefits of family planning for personal health and socio-economic stability. Educational campaigns and healthcare initiatives, especially in developing regions, have helped inform people about reproductive health and contraceptive options. This awareness is empowering individuals, particularly women, to make informed decisions about their reproductive health, leading to high demand for hormonal contraceptives. Furthermore, governments and non-governmental organizations are playing a crucial role in promoting family planning services, offering counseling, and distributing contraceptive methods. In 2017, the Government of India launched Mission Parivar Vikas to significantly improve access to contraceptives and family planning services in high-fertility districts of seven states with a total fertility rate of 3 or higher. In December 2024, the government expanded the initiative to include six North-Eastern states, alongside the original seven high-focus states, to further enhance access to contraceptives and family planning services.
Cultural shifts and social acceptance have become significant drivers in the growth of the hormonal contraceptive market. The growing awareness regarding family planning and reproductive health has led to more individuals and couples seeking contraceptive options that align with their personal and lifestyle choices. Awareness campaigns, educational initiatives, and ongoing discussions on sexual and reproductive rights have enabled individuals to make informed decisions about family planning. Also, the increasing acceptance of diverse family structures and the trend toward delayed childbearing have fueled the demand for effective, convenient, and reliable contraceptive options.
The hormonal contraceptive market is segmented on the basis of product, hormones, end user, age group, and region. On the basis of product, the market is divided into oral contraceptive pills, injectable birth control, emergency contraceptive pills, and vaginal rings, transdermal patches, and IUS & Implants. On the basis of hormones, the market is divided into progestin only contraceptive, and combined hormonal contraceptive.
On the basis of age group, the market is categorized into 15 to 24 years, 25 to 34 years, 35 to 44 years, and above 44 years. On the basis of end user, the market is segmented into hospitals, household, and clinics. On the basis of region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (France, Germany, Italy, Spain, UK, Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA).
Major key players that operate in the global hormonal contraceptive market are Teva Pharmaceutical Industries Ltd., Bayer AG, Pfizer Inc, Johnson and Johnson, AbbVie Inc., Lupin Pharmaceuticals, Inc., Organon & Co, Afaxys, Inc., Pregna International Limited, and Mayne Pharma Group Limited.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hormonal contraceptive market analysis from 2023 to 2035 to identify the prevailing hormonal contraceptive market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the hormonal contraceptive market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global hormonal contraceptive market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Patient/epidemiology data at country, region, global level
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Reimbursement Scenario
- SWOT Analysis
Key Market Segments
By Product
- Transdermal patches
- IUS and Implants
- Oral contraceptive pills
- Injectable birth control
- Emergency contraceptive pills
- Vaginal rings
By Hormone
- Progestin only contraceptive
- Combined hormonal contraceptive
By Age Group
- 15 to 24 years
- 25 to 34 years
- 35 to 44 years
- Above 44 years
By End User
- Hospitals
- Household
- Clinics
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Bayer AG
- Pfizer Inc.
- AbbVie Inc.
- Afaxys, Inc.
- Pregna International Limited
- Teva Pharmaceutical Industries Ltd.
- Lupin Pharmaceuticals, Inc.
- Mayne Pharma Group Limited
- Johnson & Johnson
- Organon & Co.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: HORMONAL CONTRACEPTIVE MARKET, BY PRODUCT
CHAPTER 5: HORMONAL CONTRACEPTIVE MARKET, BY HORMONE
CHAPTER 6: HORMONAL CONTRACEPTIVE MARKET, BY AGE GROUP
CHAPTER 7: HORMONAL CONTRACEPTIVE MARKET, BY END USER
CHAPTER 8: HORMONAL CONTRACEPTIVE MARKET, BY REGION
CHAPTER 9: COMPETITIVE LANDSCAPE
CHAPTER 10: COMPANY PROFILES
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Bayer AG
- Pfizer Inc.
- AbbVie Inc.
- Afaxys, Inc.
- Pregna International Limited
- Teva Pharmaceutical Industries Ltd.
- Lupin Pharmaceuticals, Inc.
- Mayne Pharma Group Limited
- Johnson & Johnson
- Organon & Co.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
